MOA Life Plus Co. Ltd. (KOSDAQ:142760)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,748.00
+2.00 (0.11%)
Last updated: Aug 6, 2025

MOA Life Plus Company Description

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea.

It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy.

It also provides health functional food and raw materials, and cosmetics. The company was formerly known as Bioleaders Corporation and changed its name to MOA Life Plus Co. Ltd. in March 2024.

MOA Life Plus Co. Ltd. was founded in 1999 and is headquartered in Yongin-Si, South Korea.

MOA Life Plus Co. Ltd.
CountrySouth Korea
Founded1999
IndustryBiological Products, Except Diagnostic Substances
Employees41
CEOPark Young Chul

Contact Details

Address:
A-7, 767, Sinsu-ro
Yongin-Si, 16827
South Korea
Phone82 3 1280 9650
Websitemoalifeplus.com

Stock Details

Ticker Symbol142760
ExchangeKOSDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyKRW
SIC Code2836

Key Executives

NamePosition
Park Young ChulChief Executive Officer
Hyun-Jae SungChief Financial Officer